How do different cancer subtypes arise? Do they originate from distinct cells, or from a single multipotent cell capable of ...
Anocca AB (‘Anocca’ or the ‘Company’), a clinical-stage biotechnology company developing advanced T-cell immunotherapies, today announced the successful dosing of the first patients across multiple ...
ZFTA–RELA is the cancer-promoting protein product of a gene fusion. Analyses of accessible sites in the DNA–protein complex chromatin in developing mice show that ZFTA–RELA binds to chromatin modules ...
10don MSN
Colorectal cancer has a backup plan, and it begins when mature gut cells regain stem-like traits
In a recent study, Stevens researchers have shown how colorectal cancers can evolve from mature intestinal cells that revert ...
A team led by researchers from the National Center for Tumor Diseases (NCT/UCC) Dresden at the Carl Gustav Carus University Hospital (UKD) and the Carl Gustav Carus Faculty of Medicine at the TUD ...
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...
Scientists at Pune's Agharkar Research Institute developed a nanomedicine targeting breast cancer cells by silencing key ...
A new drug targets RAS cancer-causing cells in the pancreas, nearly doubling survival rates in clinical trials. Here's how ...
Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment. However, cancer cells have developed immune evasion strategies, leading to poor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results